226700-79-4 Usage
Description
Fosamprenavir is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir. It is a sulfonamide with a structure based on that of sulfanilamide, substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-([(3S)-tetrahydrofuran-3-yloxy]carbonylamino)butyl group. Fosamprenavir is designed to improve the bioavailability and pharmacokinetics of amprenavir, making it a more effective treatment option for HIV.
Uses
Used in Pharmaceutical Industry:
Fosamprenavir is used as an antiretroviral agent for the treatment of HIV-1 infection. It works by inhibiting the HIV protease enzyme, which is essential for the replication of the virus. By blocking this enzyme, Fosamprenavir prevents the formation of mature, infectious viral particles, thus helping to control the progression of the disease.
Used in Combination Therapy:
Fosamprenavir is often used in combination with other antiretroviral drugs to enhance the treatment's effectiveness and reduce the likelihood of the virus developing resistance. This combination therapy approach is known as highly active antiretroviral therapy (HAART) and is a standard treatment for HIV-1 infection.
Used in Research and Development:
Fosamprenavir serves as a valuable compound in the ongoing research and development of new antiretroviral drugs and therapies. Its unique structure and mechanism of action provide insights into the design of future HIV treatments and contribute to the broader understanding of HIV protease inhibition.
Check Digit Verification of cas no
The CAS Registry Mumber 226700-79-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,6,7,0 and 0 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 226700-79:
(8*2)+(7*2)+(6*6)+(5*7)+(4*0)+(3*0)+(2*7)+(1*9)=124
124 % 10 = 4
So 226700-79-4 is a valid CAS Registry Number.
InChI:InChI=1/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
226700-79-4Relevant articles and documents
Methods for predicting the response to statins
-
, (2011/10/13)
The invention provides methods for optimizing therapeutic efficacy for treating hypercholesterolemia in a subject having a cardiovascular disease (CVD), comprising (a) determining subject characteristics that affect the likelihood of reaching a goal level of low density lipoprotein (LDL); and (b) obtaining success probabilities of a variety of statin treatments for reaching said goal level of LDL using said subject characteristics and a multivariate model; and (c) administrating the optimal statin treatment with the highest success probability of step (b) to said subject thereby optimizing therapeutic efficacy for treating hypercholesterolemia in said subject.
